Compounds designed to inhibit specific metabolic pathways, such as glutaminase inhibitors and mTOR inhibitors, are showing promise in clinical settings, addressing the metabolic vulnerabilities of cancer cells [122,123,124]. This evidence concerns the gene MTOR and cancer.